Investor Relations

We are a clinical-stage biotechnology company that strives to go beyond the accepted management of debilitating neurodegenerative diseases to improve the lives of patients. On the path to achieving this, we have developed SAIT, a novel therapy that stimulates the body to find and fight proteins that are central to the development and progression of these diseases.

SAIT not only benefits patients, but the technology behind it allows for fast candidate selection and the generation of new intellectual property. In addition to its lead candidate AFFITOPE® PD01 for Parkinson’s disease, AFFiRiS has programs against multiple system atrophy, dementia with Lewy bodies, and Huntington’s disease which are in pre-clinical development.

Press releases

16 September 2018 - Potential New Advances Against Huntington’s Disease

Poster presented by AFFiRiS at the 2018 European Huntington’s Disease Network Conference provides the foundation for the development of new antibody-based therapies for Huntington’s disease.

PDF-Download (Link)

27 August 2018 - A Specific Active ImmunoTherapy (SAIT) to Control Cholesterol Levels in Blood

Vienna (Austria), 27th August 2018 – Cardiovascular disease still accounts for the greatest number of deaths worldwide. PCSK9-inhibition reduces the risk of cardiovascular events by regulation of the LDL (low density lipoprotein) receptor, one of the transporters of cholesterol in blood. The protein PCSK9 binds to the LDL-cholesterol receptor and enhances its degradation, which leads to the reduced clearance of LDL-cholesterol and a higher risk of atherosclerosis.

So far, blocking PCSK9 was clinically limited by the need for frequent injections with therapeutic antibodies and economically restricted by their high cost. As a promising novel strategy, active immunotherapy that induces a long-lasting PCSK9-specific antibody response may overcome these disadvantages to reduce the burden of cardiovascular disease as the major cause of death in the developed world. On the basis of this innovative concept AFFiRiS AG. (Vienna, Austria) developed two products, AT04A and AT06A, which were tested at the Medical University of Vienna (Dept. of Clinical Pharmacology). Results of the first in-human study of this immunotherapy actively targeting PCSK9 are now available.

72 healthy individuals with slightly elevated LDL-cholesterol (75 to 200 mg/dl) were enrolled in three parallel treatment groups. Participants were randomized to receive AT04A, AT06A or placebo. Immunizations were administered as three priming immunizations at four-weekly intervals. In a second part of the study, 50 participants received a booster immunization at week 60 with a follow-up until week 90, including an interim analysis at week 70. The primary study objective was safety and tolerability of AT04A and AT06A with immunogenicity and efficacy as secondary, exploratory study objectives.

Both immunotherapies, AT04A and AT06A, were safe and well tolerated. No significant difference in the safety profile was observed between active and placebo treatment groups with the exception of injection site reactions. These local reactions – typical for vaccinations – were the most frequently reported adverse events (63.3%) and were more common in the active treatment groups. Injection site reactions were usually of mild to moderate severity, transient and not interfering with activities of daily living. More than 90% of individuals who received AT04A or AT06A developed a PCSK9-specific antibody response, which was readily reactivated after booster immunization at week 60. The mean LDL-cholesterol reduction after the booster was 13.3% at week 70 when comparing AT04A with placebo. Over the entire study period of 90 weeks, the difference in LDL-cholesterol reduction between AT04A and placebo was statistically highly significant (p<0.0001). The maximum individual reduction in LDL-cholesterol was up to 37% from baseline and was associated with a high immune response against PCSK9. LDL-cholesterol reduction persisted for at least 30 weeks after the boost immunization supporting the long-term effect of this therapy.

Prof. Martin Bauer, clinical investigator of the study and expert in clinical pharmacology, presented these results at the “Late Breaking Pharmacological Science” Session of the European Society of Cardiology (ESC) Congress on August 25th 2018 in Munich. “Specific active immunotherapy is a novel and interesting approach to target PCSK9” stated Prof. Bauer. “This was the first study to show the feasibility and safety of a specific active immunotherapy to reduce LDL-cholesterol in humans. Proof-of-concept was achieved for AT04A”.

An optimized formulation of AT04 with enhanced immunogenicity was developed and this promising candidate, called AT04B, will be tested in a next clinical trial. To fully exploit the potential of AT04B, the next study will be tested in a hyperlipidemic population in order to optimize dose, treatment schedule and efficacy. If successful, this would be the first time that an immunotherapy actively targets elevated cholesterol with long lasting efficacy to reduce the risk for coronary heart disease.

 

About AFFiRiS AG:

On the basis of its proprietary patented AFFITOME® technology, AFFiRiS develops preventative and therapeutic peptide specific active immunotherapies (SAIT) against chronic diseases. Its clinical pipeline consists of four SAIT candidates against Atherosclerosis, Parkinson´s Disease and Multiple System Atrophy. Further SAIT candidates against Alzheimer as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 165 Mio to date, half of which comes from license income and government grants. AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.

www.affiris.com

 

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
https://www.affiris.com

 

Distribution:
PR&D – Public Relations for Research & Education
Réka Ficsór
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E ficsor@prd.at
http://www.prd.at/

14 May 2018 - AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE® PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson’s Disease Patients

  • Consolidated analysis across AFF008 study series completed
  • Reevaluation of primary and secondary endpoints confirms safety and tolerability and immunogenicity profile of long-term application over 4 years of AFFITOPE® PD01A
  • Prof. Werner Poewe, Chairman of the Department of Neurology at the Medical University Innsbruck, Austria, and Leading PD Expert, Presented Results at a “Late Breaking Symposium on Treatment Strategies in PD” at the AAT-ADPD Focus Meeting in Turino, Italy on March 17

VIENNA, Austria, May 14, 2018 — AFFiRiS AG, a pharmaceutical company developing specific active immunotherapies (SAITs) for treatment of neurodegenerative diseases, announces results of their first-in-human series of studies with AFFITOPE® PD01A. In a randomized, parallel group, single-center setting, tolerability and safety of repeated subcutaneous (s.c.) administration of two doses of AFFITOPE® PD01A formulated with adjuvant to patients with early Parkinson’s disease (PD) were assessed. The studies were conducted at Confraternität by Principal Investigator Prim. Dr. Dieter Volc and were funded by a series of grants from The Michael J. Fox Foundation for Parkinson’s Research totaling nearly $3.5 million as well as a €1.4 million government-funded loan by the government agency AWS in Austria (“Austria Wirtschaftsservice”).

AFFITOPE® PD01A is a synthetically produced alpha-synuclein (aSyn)-mimicking peptide-specific active immunotherapy. In the AFF008 study series (a series of four consecutive studies), 24 patients were randomized to either AFFITOPE® PD01A low dose (15 µg) or high dose (75µg). Patients received six injections: four for priming immunizations every four weeks, and the 5th and 6th as “boost” and “reboost” immunizations (appr. 2.2 years and 3 years, respectively after the first immunization). Key objectives were to show safety and tolerability as well as immunogenicity of AFFITOPE® PD01A in a long-term outpatient treatment setting.

Summary of Key Results:

The data presented at the AAT-ADPD Focus Meeting on March 17, 2018, by Prof. Werner Poewe are from the pilot first-in-human study series in patients with early PD treated over a period of up to four years. A total of 32 patients was enrolled, 24 of them receiving active treatment and 8 PD patients on standard of care medication, who served as an observational comparison group. 21 patients in the PD01A treatment groups and five in the observational group completed the entire series of studies. At screening, the average time of PD after the first diagnosis was 2.6 years. Patients were allowed to continue their standard of care PD medication.

Safety and Tolerability:

Both doses of AFFITOPE® PD01A were locally and systemically well tolerated. No study drug-related serious adverse events (SAE) or suspected unexpected serious adverse reactions (SUSAR) occurred. No other safety signals (including data from imaging and safety lab) were reported. Systemic adverse events (AEs), standardized by the number of observed patients, resulted in 11.1 systemic AE/subject receiving AFFITOPE® PD01A versus 10.3 systemic AE/subject in the observational arm, indicating that the systemic effects of PD01A on safety were very similar to that in patients on standard of care treatment. The majority of adverse events, approximately 55%, were local reactions (LRs), the great majority of LRs being only mild and without dose dependency.

Immunogenic Profile & Clinical Scores:

AFFITOPE® PD01A showed a clear immune response against the peptide itself and cross-reactivity against aSyn targeted epitope over time. The first boost immunization produced a significant effect on all analyzed titers, resulting in the maximum titers observed in this series of studies. The second boost immunization further stabilized the produced antibody titers. Thus, a significant increase in titers against PD01A was seen over time, which translated into a humoral immune response against aSyn, being approximately one order of magnitude lower. In addition, PD01-specific antibodies were detectable in cerebrospinal fluid. Clinical scores for PD were stable during the entire study period, however, the study was not designed and not powered to evaluate clinical efficacy.

Data from post-hoc analyses indicate that AFFITOPE® PD01-induced antibodies preferentially bind to both oligomeric and fibrillar aSynwhen compared with its monomers and showed that there was a trend in reduction of oligomeric aSYN levels in plasma as well as cerebrospinal fluid upon treatment with PD01A at week 26. “Immunogenicity results after 4 years of treatment are encouraging and support the hypothesis that long-term disease management by targeting aSyn, a protein that is believed to contribute to the pathogenesis of Parkinson’s disease, with active immunotherapy seems to be feasible,” stated Prof. Werner Poewe, Chairman of the Department of Neurology at the Medical University Innsbruck, Austria, and leading PD expert. “Future trials should focus on how to translate the immune response seen in these series of studies into clinical efficacy.”

“The results of the AFF008 study series are strong encouragement for us to continue development of PD01. We have in parallel optimized the formulation of PD01 and immunization schedule for future clinical development in order to improve immunogenicity even more. Parkinson’s is a debilitating disease which puts a significant burden on patients and caregivers. They deserve our best shot at goal to bringing a potential disease-modifying therapy for long-term disease management with our unique modality to patients.” commented Oliver Siegel, CEO of AFFiRiS AG.

About the AFF008 study series:

In the 4 consecutive studies AFFiRiS008, 008E, 008A and 008AA (“AFF008 study series”), 24 patients were randomized to receive four immunizations with either low dose (15 μg) or high dose (75 μg) AFFITOPE® PD01A in intervals of four weeks on an outpatient basis (study AFF008). To extend the observation period, an additional follow-up of twelve months was added (study AFF008E). In the third part of the study series (study AFF008A), a booster immunization was performed after rerandomizing patients from study AFF008E into two different doses of boost immunization (15 μg or 75 μg AFFITOPE® PD01A). In study AFF008AA (“reboost study”), the second booster with a fixed dose of 75 μg AFFITOPE® PD01A was applied to patients previously immunized five times. Key objectives were to show safety and tolerability as well as immunogenicity of AFFITOPE® PD01A in a long-term treatment setting.

About AFFITOPE® PD01A:

AFFITOPE® PD01A targets the protein aSyn, which plays a key role in the onset and progression of Parkinson’s Disease as well as Multiple System Atrophy (MSA), an orphan disease. AFFITOPE® PD01A is a specific active immunotherapy (SAIT) and one of two SAIT candidates currently being studied in phase I studies in both indications. So far, 98 PD and MSA patients have participated in studies investigating either AFFITOPE® PD01A or PD03A. During these phase I studies, patients were observed for up to 48 months (AFFITOPE® PD01A) or 12 months (AFFITOPE® PD03A), respectively, with regard to long-term safety, immunological and clinical parameters.

About AFFiRiS AG:

On the basis of its proprietary patented AFFITOME® technology, AFFiRiS develops preventative and therapeutic peptide-specific active immunotherapies (SAIT) against chronic diseases. Its clinical pipeline consists of four SAIT candidates against PD, MSA, and Atherosclerosis. Further SAIT candidates against Alzheimer as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 165 Mio to date, half of which comes from license income and government grants. AFFiRiS is part of a consortium receiving funding from the European Union’s 7th Framework Programme under SYMPATH Grant Agreement No. 602999 (http://www.sympath-project.eu/) and MULTISYN Grant Agreement No. 602646 (http://www.multisyn.eu/). AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria. www.affiris.com

About The Michael J. Fox Foundation for Parkinson’s Research:

As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with the active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors, and volunteers. In addition to funding more than $800 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Learn more at www.michaeljfox.org.

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
W https://www.affiris.com

Distribution:
PR&D – Public Relations for Research & Education
Ira Paschinger
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E paschinger@prd.at
W http://www.prd.at

2 March 2018 - AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for both compounds as well as Immunogenicity for PD01A in early MSA patients

  • AFFITOPEs® PD01A and PD03A Safe and Well Tolerated: Primary Endpoint of Phase I Study Met
  • Immune response against AFFITOPE® PD01A and Alpha-Synuclein Seen in Patients With Early Multipe System Atrophy (MSA), an orphan disease
  • Wassilios Meissner, Principal Investigator of the Study and Leading MSA Expert, Presented Results at Today´s “Disease Modifying Treatments in the Pipeline” Session of the 6th Multiple System Atrophy Congress in New York

VIENNA, Austria, March 01, 2018 — AFFiRiS AG, a pharmaceutical company developing specific active immunotherapies (SAITs) for treatment of neurodegenerative diseases, announces results of their pilot phase 1 randomized, placebo-controlled, parallel group, patient-blinded, bi-center study, assessing the safety and exploring the immunogenicity and therapeutic activity of AFFITOPEs® PD01A and PD03A, new SAITs against alpha-synuclein (aSyn), in patients with early Multiple System Atrophy.

The study was part of SYMPATH, a collaboration of eight academic and industry partners within the 7th framework of the EU, funded by an € 6 Mio grant.

AFFITOPEs® PD01A and PD03A are synthetically produced alpha-Synuclein (aSyn)-mimicking peptide active immunotherapies. In study AFFiRiS009, 30 patients were randomized to either AFFITOPE® PD01A (75µg), AFFITOPE® PD03A (75µg) or to the placebo group treated with Alhydrogel (aluminium oxihydroxide) alone. Patients received 5 injections, 4 for priming every 4 weeks and the 5th as boost immunization 9 months after the first immunization in an outpatient setting. Key objectives were to show safety and tolerability as well as immunogenicity of AFFITOPEs® PD01A and PD03A.

Summary of key results: The data presented today by Prof. Wassilios Meissner at the 6th MSA congress in New York are from the pilot phase 1 study in patients with early MSA treated with 5 applications of either AFFITOPE® PD01A or PD03A over a period of 36 weeks. The primary endpoint of the trial was safety and tolerability of repeated s.c. administration of AFFITOPEs® PD01A or PD03A. A total of 30 patients were enrolled with 6 patients of the active treatment groups discontinuing early. At screening, the average time of MSA after first diagnosis was between 0.6-0.8 years. Patients were allowed to continue their standard of care MSA medication.

Safety and Tolerability: Both AFFITOPEs® PD01A and PD03A were locally and systemically well tolerated. Two patients died during study participation and one patient shortly afterwards. This is in line with the safety results of other MSA trials reporting a mortality rate of up to 10%. No evidence of significantly more progression of motor impairment was seen in the active treatment groups compared to the placebo group. No other safety signals (including data from imaging and safety lab) were reported. Overall, the extensive monitoring of patient’s safety during study AFF009 did not evidence any safety concern associated with AFFITOPE® PD01A and PD03A administration. The majority of adverse events (AE), appr. 30%, were local reactions (LRs), the great majority of LRs being only mild.

Immunogenic Profile: AFFITOPE® PD01A showed a clear immune response against the peptide itself and crossreactivity against aSyn targeted epitope over time, and showed antibody reactivation upon booster immunization. Regarding the immunogenicity of AFFITOPE® PD03A, no significant differences were seen compared to placebo.

Conclusions: AFFITOPEs® PD01A and PD03A were well tolerated in early MSA patients. PD01A induced a clear immune response versus the peptide itself and aSyn epitope.

“The safety profile of both compounds are in line with our expectations and similar to what we have seen in other MSA studies with a follow-up period of 52 weeks” stated Prof. Wassilios Meissner, PI of the study, Chairman of the the French Reference Center for MSA at the Bordeaux University Hospital, and leading MSA expert. “The immunogenicity profile of AFFITOPE® PD01A looks encouraging and seems to indicate that patients with early MSA elicit an antibody response specific to alpha synuclein, a protein that is believed to be contributing to the pathogenesis of the disorder.” Oliver Siegel, CEO of AFFiRiS AG explained: “Further clinical development of PD01A will focus on its pharmacodynamic and pharmacokinetic properties in synucleinopathies. The board will take a decision on the next clinical trial once we have further consulted with our key opinion leaders and after having evaluated the results of all our studies.”

About AFFITOPEs® PD01A and PD03A:

AFFITOPEs® PD01A and PD03A target the protein aSyn, which plays a key role in the onset and progression of Multiple System Atrophy (MSA) as well as Parkinson´s Disease (PD). Both AFFITOPE® PD01A and PD03A are specific active immunotherapies and have been studied in phase I studies. So far, 98 PD and MSA patients have participated in studies investigating either AFFITOPE® PD01A or PD03A. During these phase I studies patients were observed for up to 48 months (AFFITOPE® PD01A) or 12 months (AFFITOPE® PD03A), respectively, with regard to long-term safety, immunological and clinical parameters.

About SYMPATH:

AFFiRiS has launched the collaborative research project SYMPATH with funding from FP7 to forward the clinical development of the aSyn targeting vaccines AFFITOPE® PD01A and PD03A together with experts from three European countries including Austria, Germany and France. SYMPATH implemented a tandem phase I program to evaluate the safety and explore the activity of these two active immunotherapy candidates in humans. A part of the program is devoted to the identification of biomarkers with diagnostic and prognostic value. The cause of both MSA and PD are not fully understood and currently there are no treatment options available for either to alter the course of the disease.

About AFFiRiS AG:

On the basis of its AFFITOME technology, AFFiRiS develops preventative and therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of four vaccine candidates against PD, MSA and Atherosclerosis. Further vaccine candidates against Alzheimer as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 165 Mio to date, half of which comes from license income and government grants. AFFiRiS is part of a consortium receiving funding from the European Union’s 7th Framework Programme under SYMPATH Grant Agreement No. 602999 (http://www.sympath-project.eu/) and MULTISYN Grant Agreement No. 602646 (http://www.multisyn.eu/). AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
W https://www.affiris.com

Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

20 June 2017 - A vaccine to immunise people against high levels of cholesterol and the narrowing of the arteries caused by build-up of fatty material (atherosclerosis) may be possible following successful results in mice. Now, a phase I trial in patients has started to see if the findings translate to humans

The study, which is published today (Tuesday) in the European Heart Journal [1], is the first to show that it is possible to immunise genetically modified mice with a molecule that causes the body to produce antibodies against an enzyme called PCSK9 (Proprotein covertase subtilisin/kexin type 9), which plays a role in preventing the clearance of low density lipoprotein cholesterol (“bad” cholesterol) from the blood.

People with high levels of LDL cholesterol, either due to their genetic inheritance, or to poor diet and lifestyles, are at much greater risk of developing cardiovascular disease prematurely. These diseases of the heart and blood vessels, caused by atherosclerosis, have overtaken infections as the main cause of illness and death throughout the world. At present, drugs such as statins can be used to lower LDL cholesterol, but they have to be taken on a daily basis and although they are generally well-tolerated they can cause adverse side effects in some people. The most recently approved cholesterol-lowering compounds are monoclonal antibodies targeting PCSK9, which are highly effective, but their effect is short-lived, resulting in frequent re-application and high costs.

The research published today shows that the AT04A vaccine, when injected under the skin in mice that have been fed fatty, Western-style food in order to induce high cholesterol and the development of atherosclerosis, reduced the total amount of cholesterol by 53%, shrank atherosclerotic damage to blood vessels by 64%, and reduced biological markers of blood vessel inflammation by 21-28%, compared to unvaccinated mice. Furthermore, the induced antibodies remained functional over the whole study period and concentrations were still high at the end of the study.

Dr Günther Staffler, chief technology officer at AFFiRis (the company that developed AT04A) and one of the authors of the study, said: “AT04A was able to induce antibodies that specifically targeted the enzyme PCSK9 throughout the study period in the circulation of the treated mice. As a consequence, levels of cholesterol were reduced in a consistent and long-lasting way, resulting in a reduction of fatty deposits in the arteries and atherosclerotic damage, as well as reduced arterial wall inflammation.

“The reduction in total cholesterol levels was significantly correlated with induced antibody concentration, proving that induced antibodies caused the reduction in cholesterol and also are ultimately responsible for the reduction of atherosclerosis development. As antibody concentrations remained high at the end of the study, it can be assumed they would continue to reduce cholesterol levels for some time afterwards, resulting in a long-lasting effect, as has been shown in previous studies.

“If these findings translate successfully into humans, this could mean that, as the induced antibodies persist for months after a vaccination, we could develop a long-lasting therapy that, after the first vaccination, just needs an annual booster. This would result in an effective and more convenient treatment for patients, as well as higher patient compliance.”

The enzyme PCSK9 is made in the liver and it locks on to LDL cholesterol receptors, reducing their ability to get rid of LDL cholesterol from the blood. When injected, AT04A causes the body to produce antibodies that block the function of PCSK9, so that the activity of the LDL cholesterol receptors is increased.

“The way that AT04A is administered is comparable to a vaccine,” explained Dr Staffler. “However, the difference between a conventional vaccine and our approach is that a vaccine induces antibodies that are specific to bacterial or viral proteins that are foreign to the body – pathogens – whereas AT04A induces antibodies against a target protein that is produced by the body – endogenous proteins. This it is really an immunotherapeutic approach rather than a vaccine approach.”

In 2015, a phase I clinical study [2] started at the Department of Clinical Pharmacology, Medical University of Vienna, Austria, studying AT04A and another molecule AT06A in 72 healthy people to assess its safety and activity. The study is expected to complete at the end of this year.

In an accompanying editorial [3], Professor Ulrich Laufs, of Saarland University, Germany, and Professor Brian Ference, of the University of Bristol, UK, and the Wayne State University School of Medicine, Detroit, USA, write: “It appears promising to further evaluate long-term LDL cholesterol lowering by vaccination against PCSK9 for the prevention of atherosclerotic events.” However, they say that “safety, the response in humans and the very important but unknown long-term immune effects need to be very carefully addressed during the course of clinical development”. In particular, reductions in total cholesterol via statins and other drugs are associated with an increase in new onset diabetes. “Therefore, one potential safety concern for long-term lowering of LDL cholesterol with a vaccine directed against PCSK9 is the potential for an increased risk of new onset diabetes. In the short term, the LDL cholesterol lowering effect of statins and PCS9 inhibitors appears to far outweigh the risks of new onset diabetes.”

Notes:
[1] “The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice”, by Christine Landlinger et al. European Heart Journal. doi:10.1093/eurheartj/ehx260.
[2] Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)”. ClinicalTrials.gov Identifier: NCT02508896
[3] “Vaccination to prevent atherosclerotic cardiovascular disease”, by Ulirich Laufs and Brian Ference. European Heart Journal. doi:10.1093/eurheartj/ehx302

The European Heart Journal is the flagship journal of the European Society of Cardiology (http://www.escardio.org). It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press. Please acknowledge the journal as a source in any articles.

PDF-Download (Link)

7 June 2017 - AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE® PD03A, Confirming Immunogenicity and Safety Profile in Parkinson’s Disease Patients

  • AFFITOPE® PD03A Safe and Well Tolerated: Primary Endpoint of Phase I Study Met
  • Dose Dependent Immune Response Against AFFITOPE® PD03A and Alpha-Synuclein Seen in Patients With Early Parkinson’s Disease
  • Prof. Werner Poewe, PI of the Study and Leading PD Expert, Presented Results at Today´s Plenary Session of the 21 Iternational Congress of Parkinson´s Disease and Movement Disorders in Vancouver, Canada

VIENNA, Austria, June 07, 2017 — AFFiRiS AG, a pharmaceutical company developing novel active immunotherapies for treatment of neurodegenerative diseases, announces top line results of their pilot phase 1 randomized, placebo-controlled, parallel group, patient-blinded, bi-center study, assessing tolerability and safety of repeated subcutaneous (s.c.) administration of two doses of AFFITOPE® PD03A formulated with adjuvant to patients with early Parkinson’s disease (PD). The study is part of SYMPATH, a collaboration of eight academic and industry partners within the 7th framework of the EU, funded by an € 6 Mio grant. AFFITOPE® PD03A is a synthetically produced alpha-Synuclein (aSyn)-mimicking peptide vaccine. In study AFFiRiS011, 36 patients were randomized to either AFFITOPE® PD03A high dose (75μg), low dose (15 μg) or to the placebo group treated with Alhydrogel (aluminium oxihydroxide) alone. Patients received 5 injections, 4 for priming every 4 weeks and the 5th as boost immunization 9 months after the first immunization in an outpatient setting. Key objectives were to show safety and tolerability as well as immunogenicity of AFFITOPE® PD03A. Summary of key top level results: The data presented today by Prof. Werner Poewe on behalf of the SYMPATH partners at the 21st International Congress of Parkinson´s Disease and Movement Disorders in Vancouver are from the pilot phase 1 study in patients with early PD treated with 5 applications of AFFITOPE® PD03A over a period of 36 weeks. The primary endpoint of the trial was safety and tolerability of repeated s.c. administration of AFFITOPE® PD03A. A total of 39 patients were screened, 36 treated with 1 patient of the control group discontinuing early. At screening, the average time of PD after first diagnosis was between 1.6-2.3 years; Patients were allowed to continue their standard of care PD medication. Safety and Tolerability: Both doses were locally and systemically well tolerated. No study drug related serious adverse events (SAE) or suspected unexpected serious adverse reactions (SUSAR) occurred. The majority of adverse events (AE), appr. 59%, were local reactions (LRs), the great majority of LRs being only mild and without dose dependency. Immunogenic Profile: AFFITOPE® PD03A showed a clear dose dependent immune response against the peptide itself and crossreactivity against aSyn targeted epitope over time, and showed antibody reactivation upon booster immunization.

Conclusions: 15 and 75μg of AFFITOPE® PD03A were well tolerated in early PD patients. The compound induced a clear dose dependent immune response versus AFFITOPE® PD03A and aSyn epitope.

“The immunogenicity profile looks encouraging and supports the hypothesis that patients elicit an antibody response specific to alpha synuclein, a protein that is believed to be contributing to the pathogenesis of Parkinson’s” stated Prof. Werner Poewe, PI of the study, Chairman of the Department of Neurology at the Medical University Innsbruck, Austria, and leading PD expert. “Based on additional data covering alpha synuclein lowering in plasma and cerebrospinal fluid (CSF), expected in Q3 2017 we should see clearer about PD01A vs PD03A for future development in Parkinson´s patients.”

About AFFITOPE® PD03A:

AFFITOPE® PD03A targets the protein aSyn, which plays a key role in the onset and progression of PD as well as Multiple System Atrophy (MSA), an orphan disease. AFFITOPE® PD03A is one of two vaccine candidates currently being studied in phase I studies. So far, 98 PD and MSA patients have participated in studies investigating either AFFITOPE® PD01A or PD03A. During these phase I studies patients were observed for up to 48 months (AFFITOPE® PD01A) or 12 months (AFFITOPE® PD03A), respectively, with regard to long-term safety, immunological and clinical parameters. Final results of studies with both compounds are expected for Q4 2017.

About SYMPATH:

AFFiRiS has launched the collaborative research project SYMPATH with funding from FP7 to forward the clinical development of the aSyn targeting vaccines AFFITOPE® PD01A and PD03A together with experts from three European countries including Austria, Germany and France. SYMPATH implemented a tandem phase I program to evaluate the safety and explore the activity of these two active immunotherapy candidates in humans. A part of the program is devoted to the identification of biomarkers with diagnostic and prognostic value. The cause of both PD and MSA are not fully understood and currently there are no treatment options available for either to alter the course of the disease.

About AFFiRiS AG:

On the basis of its proprietary patented AFFITOME® technology, AFFiRiS develops preventative and therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of four vaccine candidates against PD, MSA and Atherosclerosis. Further vaccine candidates against Alzheimer as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 156 Mio to date, half of which comes from license income and government grants. AFFiRiS has received grants of $ 3 Mio for its phase I studies with AFFITOPE® PD01A from The Michael J. Fox Foundation (MJFF). Furthermore, AFFiRiS is part of collaborative projects receiving funding from the European Union’s 7th Framework Programme under SYMPATH Grant Agreement No. 602999 (http://www.sympath-project.eu/) and MULTISYN Grant Agreement No. 602646 (http://www.multisyn.eu/). AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.

www.affiris.com

Contact AFFiRiS AG: Bettina Wessa Karl-Farkas-Gasse 22 1030 Vienna, Austria T +43 / (0)1 / 798 15 75 – 300 E bettina.wessa@affiris.com W https://www.affiris.com

Distribution: PR&D – Public Relations for Research & Education Mariannengasse 8 1090 Vienna, Austria T +43 / (0)1 / 505 70 44 E contact@prd.at W http://www.prd.at

PDF-Download (Link)

2 May 2017 - AFFiRiS AG successfully raises €10m equity financing

  • €10 m additional capital raised

Vienna, 2nd May 2017. AFFiRiS AG has successfully completed its capital increase and raises an additional
€ 10m from existing investors.

In an annual general meeting on 25th April 2017 the shareholders of the company have agreed to a capital
increase of € 10m. The new shares have been subscribed by the two major investors of the company, Santo
Holding – the family office of the Strüngmann family – the MIG Funds advised by MIG Verwaltungs AG and the
FCPB Affi GmbH.
AFFIRIS commenced Phase 1 clinical development of its Hypercholesterolemia and Atherosclerosis prevention
active immunotherapy candidates AT04A and AT06A and expects data from this study in Q2 2017. AT04A and
AT06A are vaccine candidates from the next generation AFFITOME technology and target PCSK9, an enzyme
which plays a role in the lipid metabolism of the liver. In addition, AFFiRiS expects to complete an exploratory
Phase 1 development program in three ongoing clinical trials with its active immunotherapy candidates PD01A
and PD03A targeting oligomeric forms of alpha synuclein in Parkinson’s and Multiple System Atrophy (MSA)
patients in Q4 2017. AFFiRiS enjoys the continous support of The Michael J. Fox Foundation, the world’s largest
nonprofit funder of Parkinson’s research.

About AFFiRiS AG:
On the basis of its AFFITOME-technolgy, AFFiRiS develops tailor-made active
immunotherapes against chronic diseases. Its clinical pipeline consists of 3 active immunotherapeutic
candidates against Parkinson’s, MSA and Hypercholesterolemia. Further candidates against diabetes, allergies,
asthma as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding
of approx. € 146m to date, half of which comes from license income and government grants. AFFiRiS currently
employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.

www.affiris.com

 

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Wien
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
W https://www.affiris.com

 

Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

PDF-Download (Link)

7 September 2016 - Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine against Alpha-Synuclein

  • PD01A was Safe and Well Tolerated: Primary Endpoint of Phase I “Boost” Study Met
  • Immune Response was Seen in 86% of Patients, Resulting in an Increase of Responder Rate after Boost Immunization
  • PD01A-induced Antibodies Preferentially Bind to Fibrilic Alpha-Synuclein (aSyn)
  • Data will be Presented at the Poster Tour of Leading Abstracts at the 4th World Parkinson Congress in Portland, Oregon, USA on September 21

VIENNA, Austria, September 07, 2016 — AFFiRiS AG announced today results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE® PD01A, an active vaccine against Parkinson´s disease (PD).The study was funded by a $1.04 million grant from The Michael J. Fox Foundation for Parkinson’s Research.

The “boost” study AFF008A was designed to assess one boost immunization with AFFITOPE® PD01A per patient with regard to safety/tolerability and immunological and clinical activity in those patients who had already received the vaccine (four “priming” vaccinations at four-week intervals) within the first-in-man clinical study AFF008. Six PD patients on best medical care, including standard symptomatic medication, served as a comparison group. In the “boost” study, two different doses of AFFITOPE® PD01A (15 μg and 75 μg) were again safe and well tolerated, meeting the primary endpoint of the trial.

Patients belonging to the low-dose group of AFF008 were randomized in two equally distributed groups receiving either 15 μg or 75 μg AFFITOPE® PD01A. The same was done with patients of the AFF008 high-dose group, in order to allow for evaluation of four different vaccination schedules.

Across all patients, no antibody concentration limiting toxicity was observed. Adverse events were similar across all five groups except injection site reactions, which only occurred in the active treatment groups, and psychiatric disorders, reported at a lower rate in the active groups. All of the 28 patients completed the study and received all planned vaccinations. Only one serious adverse event was reported, which was classified as being not related to AFFITOPE® PD01A administration.

An immune response against AFFITOPE® PD01A was seen in 19 of 22 (86%) of vaccinated patients and 12 of 19 (63%) of these responders generated aSyn-specific serum antibodies. The immune response sustained throughout the entire observation period of 24 weeks. Patients on low dose and then high dose had a clear immunological boost. This data supports that further dose and scheduling may significantly influence antibody titer/concentration and further studies need to be performed. Additionally, vaccine-induced antibodies were detectable in cerebrospinal fluid. This induction of antibodies against aSyn supports the concept of the principle of AFFiRiS’ proprietary therapeutic vaccine.

Parallel laboratory experiments using recombinant aSyn protein to assess selectivity showed that AFFITOPE® PD01A-induced antibodies preferentially bind to aSyn fibrils, which are believed to be the toxic form of the protein, as compared to the monomeric form.

Due to the limitations of the Phase I trial design (the study was not double-blind, and assignment to the comparison group was not randomized), it is not known whether effects seen in the active groups are indicative of treatment effects or due to confounding factors. Efficacy variables were evaluated in an explorative manner with regard to the small sample size. Preliminary observations showed that in eight of the 19 (42%) immunological responders, no increase of the concomitant dopaminergic PD medication was needed throughout the observational period (on average three years per subject). Among the same group, five of eight (63%) patients had stable UPDRS III scores at the end of the “boost” study.

Continuous efforts are undertaken to follow this patient cohort and to further characterize their immunological and clinical response to treatment with AFFITOPE® PD01A. The next study, AFF008AA, is focusing primarily on the long-term safety and, in addition, on the assessment of the immunological and clinical effects of a second boost vaccination (“reboost”). That study is also funded by The Michael J. Fox Foundation, as was the AFF008 trial. Recruitment of patients for AFF008AA has been completed; results are expected in Q2 2017.

About AFFITOPE® PD01A:
AFFITOPE® PD01A targets the protein alpha-Synuclein, which plays a key role in the onset and progression of Parkinson’s as well as multiple system atrophy (MSA), an orphan disease. During the first-in-man study AFF008, AFFITOPE® PD01A was safe and well tolerated, meeting the primary endpoint of the trial. PD01A is one of two vaccine candidates currently being studied in three ongoing Phase 1 studies AFF008AA, AFF009 and AFF011 in which currently 92 Parkinson’s and Multiple System Atrophy (MSA) patients are receiving either PD01A or PD03A. During these phase I studies patients are being observed for up to 48 months with regard to long-term safety, immunological and clinical parameters. Results are expected for Q4 2017.

About AFFiRiS AG:
On the basis of its AFFITOME-technology, AFFiRiS develops preventative and therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of four vaccine candidates against Parkinson’s, MSA and Atherosclerosis prevention. Further vaccine candidates against diabetes, allergies as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 130m to date, half of which comes from license income and government grants. Furthermore, AFFiRiS is part of collaborative projects receiving funding from the European Union’s Seventh Framework Programme under SYMPATH Grant Agreement No. 60299 (http://www.sympath-project.eu/) and MULTISYN Grant Agreement No. 602646 (http://www.multisyn.eu/). AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
www.affiris.com

About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $600 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Learn more at www.michaeljfox.org.

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Wien, Austria
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
W https://www.affiris.com

 

Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

PDF-Download (Link)

23 June 2016 - AFFiRiS AG successfully raises €10m equity financing

  • €10 m additional capital raised
  • Günther Staffler appointed as Chief Technology Officer
  • Noel Barrett appointed as additional member of the supervisory board

Vienna, 23 June 2016. AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016.

In an extraordinary shareholders meeting on 29. April 2016 the shareholders of the company have agreed to a capital increase of € 10m. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – ,the MIG Funds advised by MIG Verwaltungs AG and new investor FCPG Affi GmbH. In the ordinary shareholders meeting on 15. June 2016 the shareholders also elected Noel Barrett as additional member of the Supervisory Board. He replaces Dr. Frank Mattner whose tenure as supervisory board member has ended on 31. December 2015.

Noel Barrett has more than 30 years’ experience in the vaccines and biotechnology industry with management responsibilities covering the complete development process required to bring vaccine products to the market. In his last position at Baxter HealthcareBaxalta Noel Barrett was Vice President, Global R&D Baxter Vaccines and has successfully overseen the development of numerous vaccine candidates through preclinical and clinical development.

Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS commented: “We are excited to welcome Noel Barrett to the Supervisory Board of AFFiRiS. His product development expertise he will be tremendously valuable as the company focused on advancing its projects in clinical development.”

The company has decided to adapt its management structure to focus on development, both preclinical and clinical of its projects. All preclinical development will be led by Günther Staffler (48) whom the Supervisory Board has appointed as Chief Technology Officer and member of the executive board of AFFiRiS. Günther Staffler has previously been responsible as Head of Immunology for the preclinical development of its vaccine candidates AT04 and AT06 in Hypercholesterolemia and Atherosclerosis prevention which are currently being tested in Phase 1 clinical development. The company also announces the departure of Achim Schneeberger, previously Chief Medical Officer and Arne von Bonin, Chief Scientific Officer.

AFFIRIS commenced Phase 1 clinical development of its Hypercholesterolemia and Atherosclerosis prevention vaccine candidates AT04A and AT06A and expects data from this study in Q1 2017. AT04A and AT06A are vaccine candidates from the next generation AFFITOME technology and target PCSK9, an enzyme which plays a role in the lipid metabolism of the liver. If PCSK9 is blocked, more LDL receptors will be present on the surface of the liver and will remove more LDL cholesterol from the blood. Therefore, blocking PCSK9 can lower blood cholesterol levels.

About AFFiRiS AG:
On the basis of its AFFITOME-technolgy, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of 3 drug candidates against Parkinson’s, MSA and Hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 130m to date, half of which comes from license income and government grants. AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
www.affiris.com

 

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Wien
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com
W https://www.affiris.com

 

Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

PDF-Download (Link)

16 June 2015 - Vaccine Specialist AFFiRiS AG successfully completes Financing Round

  • € 10m additional capital raised
  • Supervisory Board appoints Oliver Siegel as Chief Executive Officer
  • Prof. Dr. Christoph Huber elected to Supervisory Board

Vienna, 16 June 2015. AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the Supervisory Board as of 18 May 2015 and replaces Dr. Walter Schmidt who has decided to leave the Supervisory Board. Mag. Vera Bürger and Claudia Juno have been appointed by the employees to join the Supervisory Board.

In an extraordinary shareholders meeting on 18 May 2015 the shareholders of the company have agreed to a capital increase of € 10m. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – and the MIG Funds represented by MIG Verwaltungs AG. The shareholders also elected Prof. Dr. Christoph Huber as member of the Supervisory Board. He will replace Dr. Walter Schmidt who has decided to leave the Supervisory Board. Walter Schmidt co-founded AFFiRiS eleven years ago and profoundly influenced the company until his resignation from operational responsibilities this past January.

Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS said: “Walter Schmidt has been instrumental in shaping AFFiRiS. His business acumen and his entrepreneurship have been critical in establishing the AFFITOME-technology as a leading platform for active immune therapy in the prevention and therapy of chronic illnesses. I am pleased to welcome Prof. Christoph Huber to the Supervisory Board. His outstanding scientific achievements in the field of immunology and his entrepreneurial spirit as founder of various successful biotech companies will be of great value to the future development of AFFiRiS.” The Supervisory Board appointed Oliver Siegel (49) as Chief Executive Officer and Dr. Arne von Bonin (51) as Chief Scientific Officer (CSO).

The new capital allows the company to further advance its AFFITOME-technology for the prevention and therapy of chronic illnesses. Oliver Siegel comments these developments: “The successful capital increase demonstrates the continued support from our investors in the technology and the scientific team. The ongoing support will be essential to the successful development of our vaccine technology as platform technology in a number of indications.”
Recently, AFFIRIS presented Phase 1 data on its Parkinson’s vaccine candidate PD01. PD01A was the first α-synuclein targeting drug candidate that successfully completed a phase 1 study. α-synuclein is a protein which plays a role in the pathological processes of neurodegenerative diseases such as Parkinson’s. The program enjoys the support from The Michael J. Fox Foundation, the world’s largest nonprofit funder of Parkinson’s research.
About AFFiRiS AG:
On the basis of its proprietary patented AFFITOME-technology, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Currently, its clinical pipeline consists of 3 drug candidates against Parkinson’s, MSA and Hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma as well as Huntington’s disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 120m to date, half of which comes from license income and government grants. AFFiRiS currently employs 57 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
www.affiris.com

 

Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 300
E bettina.wessa@affiris.com

 

Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

PDF-Download (Link)

WHERE TO MEET US

17th Annual Eyeforpharma Conference 2019
12–14 March 2019
Barcelona, Spain
Redefining Early Stage Investments (RESI)
25 March 2019
Vienna, Austria
13th Annual International Partnering Conference, Bio-Europe Spring 2019
25–27 March, 2019
Vienna, Austria
14th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2019
26–31 March, 2019
Lisbon, Portugal
Outsourcing in Clinical Trials (OCT) Europe 2019
14–15 May 2019
Milan, Italy
Neurotech Investing & Partnering Conference 2019
21–22 May 2019
Boston, USA
BIO International Convention 2019
3–6 June 2019
Philadelphia, USA
14th Felasa Congress 2019
10–13 June 2019
Prague, Czech Republic
Synuclein Meeting 2019
1–4 September 2019
Porto, Portugal
International Congress of Parkinson’s Disease and Movement Disorders 2019
22–26 September 2019
Nice, France